REPLIGEN CORP (RGEN) Stock Fundamental Analysis
NASDAQ:RGEN - Nasdaq - US7599161095 - Common Stock - Currency: USD
We assign a fundamental rating of 5 out of 10 to RGEN. RGEN was compared to 54 industry peers in the Life Sciences Tools & Services industry. RGEN has an excellent financial health rating, but there are some minor concerns on its profitability. RGEN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RGEN was profitable.
RGEN had a positive operating cash flow in the past year.
RGEN had positive earnings in 4 of the past 5 years.
RGEN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
RGEN has a Return On Assets of -0.69%. This is in the better half of the industry: RGEN outperforms 61.11% of its industry peers.
RGEN's Return On Equity of -0.99% is fine compared to the rest of the industry. RGEN outperforms 64.81% of its industry peers.
RGEN has a Return On Invested Capital (0.48%) which is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for RGEN is significantly below the industry average of 16.00%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.69% | ||
| ROE | -0.99% | ||
| ROIC | 0.48% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
1.3 Margins
With a Operating Margin value of 2.56%, RGEN perfoms like the industry average, outperforming 59.26% of the companies in the same industry.
In the last couple of years the Operating Margin of RGEN has declined.
The Gross Margin of RGEN (51.03%) is comparable to the rest of the industry.
RGEN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.56% | ||
| PM (TTM) | N/A | ||
| GM | 51.03% |
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RGEN is destroying value.
RGEN has more shares outstanding than it did 1 year ago.
RGEN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for RGEN has been reduced compared to a year ago.
2.2 Solvency
RGEN has an Altman-Z score of 5.24. This indicates that RGEN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of RGEN (5.24) is better than 85.19% of its industry peers.
The Debt to FCF ratio of RGEN is 4.42, which is a neutral value as it means it would take RGEN, 4.42 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 4.42, RGEN is doing good in the industry, outperforming 66.67% of the companies in the same industry.
RGEN has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of RGEN (0.27) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.42 | ||
| Altman-Z | 5.24 |
ROIC/WACC0.05
WACC9.81%
2.3 Liquidity
RGEN has a Current Ratio of 6.79. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
RGEN has a Current ratio of 6.79. This is amongst the best in the industry. RGEN outperforms 87.04% of its industry peers.
RGEN has a Quick Ratio of 5.79. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 5.79, RGEN belongs to the best of the industry, outperforming 85.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.79 | ||
| Quick Ratio | 5.79 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 39.32% over the past year.
RGEN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.11% yearly.
The Revenue for RGEN has decreased by -11.36% in the past year. This is quite bad
Measured over the past years, RGEN shows a quite strong growth in Revenue. The Revenue has been growing by 18.62% on average per year.
EPS 1Y (TTM)39.32%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%12.12%
Revenue 1Y (TTM)-11.36%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%18.36%
3.2 Future
Based on estimates for the next years, RGEN will show a very strong growth in Earnings Per Share. The EPS will grow by 25.08% on average per year.
Based on estimates for the next years, RGEN will show a quite strong growth in Revenue. The Revenue will grow by 15.37% on average per year.
EPS Next Y15.8%
EPS Next 2Y22.1%
EPS Next 3Y23.83%
EPS Next 5Y25.08%
Revenue Next Year11.95%
Revenue Next 2Y13.13%
Revenue Next 3Y14.1%
Revenue Next 5Y15.37%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 69.06 indicates a quite expensive valuation of RGEN.
Compared to the rest of the industry, the Price/Earnings ratio of RGEN is on the same level as its industry peers.
The average S&P500 Price/Earnings ratio is at 26.99. RGEN is valued rather expensively when compared to this.
RGEN is valuated quite expensively with a Price/Forward Earnings ratio of 51.02.
Compared to the rest of the industry, the Price/Forward Earnings ratio of RGEN is on the same level as its industry peers.
RGEN is valuated rather expensively when we compare the Price/Forward Earnings ratio to 36.36, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 69.06 | ||
| Fwd PE | 51.02 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as RGEN.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of RGEN is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 52.82 | ||
| EV/EBITDA | 53.98 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as RGEN's earnings are expected to grow with 23.83% in the coming years.
PEG (NY)4.37
PEG (5Y)9.72
EPS Next 2Y22.1%
EPS Next 3Y23.83%
5. Dividend
5.1 Amount
No dividends for RGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:RGEN (8/7/2025, 3:31:04 PM)
112.57
+0.47 (+0.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners104.63%
Inst Owner Change-0.57%
Ins Owners0.51%
Ins Owner Change-0.5%
Market Cap6.32B
Analysts80.71
Price Target183.61 (63.11%)
Short Float %6.48%
Short Ratio4.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.97%
Min EPS beat(2)5.21%
Max EPS beat(2)10.73%
EPS beat(4)3
Avg EPS beat(4)10.26%
Min EPS beat(4)-0.8%
Max EPS beat(4)25.89%
EPS beat(8)5
Avg EPS beat(8)9.59%
EPS beat(12)9
Avg EPS beat(12)11.22%
EPS beat(16)13
Avg EPS beat(16)15.65%
Revenue beat(2)1
Avg Revenue beat(2)-0.4%
Min Revenue beat(2)-2.03%
Max Revenue beat(2)1.23%
Revenue beat(4)1
Avg Revenue beat(4)-0.93%
Min Revenue beat(4)-2.03%
Max Revenue beat(4)1.23%
Revenue beat(8)1
Avg Revenue beat(8)-1.77%
Revenue beat(12)3
Avg Revenue beat(12)-0.5%
Revenue beat(16)7
Avg Revenue beat(16)1.4%
PT rev (1m)-1.42%
PT rev (3m)-2.89%
EPS NQ rev (1m)-0.98%
EPS NQ rev (3m)0.5%
EPS NY rev (1m)0.08%
EPS NY rev (3m)-1.55%
Revenue NQ rev (1m)0.11%
Revenue NQ rev (3m)0.22%
Revenue NY rev (1m)0.18%
Revenue NY rev (3m)1.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 69.06 | ||
| Fwd PE | 51.02 | ||
| P/S | 7.87 | ||
| P/FCF | 52.82 | ||
| P/OCF | 43.41 | ||
| P/B | 3.19 | ||
| P/tB | 12.81 | ||
| EV/EBITDA | 53.98 |
EPS(TTM)1.63
EY1.45%
EPS(NY)2.21
Fwd EY1.96%
FCF(TTM)2.13
FCFY1.89%
OCF(TTM)2.59
OCFY2.3%
SpS14.3
BVpS35.34
TBVpS8.79
PEG (NY)4.37
PEG (5Y)9.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.69% | ||
| ROE | -0.99% | ||
| ROCE | 0.76% | ||
| ROIC | 0.48% | ||
| ROICexc | 0.65% | ||
| ROICexgc | 2.53% | ||
| OM | 2.56% | ||
| PM (TTM) | N/A | ||
| GM | 51.03% | ||
| FCFM | 14.9% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
ROICexc(3y)3.74%
ROICexc(5y)4.93%
ROICexgc(3y)17.96%
ROICexgc(5y)N/A
ROCE(3y)4.23%
ROCE(5y)5.26%
ROICexcg growth 3Y-71.22%
ROICexcg growth 5Y-37.94%
ROICexc growth 3Y-63.64%
ROICexc growth 5Y-32.38%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
F-Score5
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.42 | ||
| Debt/EBITDA | 4.66 | ||
| Cap/Depr | 27.92% | ||
| Cap/Sales | 3.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 128.29% | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.79 | ||
| Quick Ratio | 5.79 | ||
| Altman-Z | 5.24 |
F-Score5
WACC9.81%
ROIC/WACC0.05
Cap/Depr(3y)88.31%
Cap/Depr(5y)109.53%
Cap/Sales(3y)7.3%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.32%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%12.12%
EPS Next Y15.8%
EPS Next 2Y22.1%
EPS Next 3Y23.83%
EPS Next 5Y25.08%
Revenue 1Y (TTM)-11.36%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%18.36%
Revenue Next Year11.95%
Revenue Next 2Y13.13%
Revenue Next 3Y14.1%
Revenue Next 5Y15.37%
EBIT growth 1Y739.35%
EBIT growth 3Y-59.22%
EBIT growth 5Y-19.7%
EBIT Next Year72.43%
EBIT Next 3Y40.62%
EBIT Next 5Y36.8%
FCF growth 1Y32.01%
FCF growth 3Y45.03%
FCF growth 5Y27.02%
OCF growth 1Y-9.06%
OCF growth 3Y13.8%
OCF growth 5Y21.15%